Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Shares Outstanding (Weighted Average) for 11 consecutive years, with $4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) fell 1.17% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Sep 2025, down 1.17%, and an annual FY2024 reading of $3.9 million, up 619.81% over the prior year.
  • Shares Outstanding (Weighted Average) was $4.2 million for Q3 2025 at Kiora Pharmaceuticals, up from $3.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $13.1 million in Q2 2022 and bottomed at $212612.0 in Q3 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $3.3 million, with a median of $3.2 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) crashed 97.2% in 2023, then surged 864.68% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $241099.0 in 2021, then soared by 251.94% to $848534.0 in 2022, then tumbled by 36.6% to $538007.0 in 2023, then soared by 619.81% to $3.9 million in 2024, then increased by 7.56% to $4.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for KPRX at $4.2 million in Q3 2025, $3.9 million in Q2 2025, and $4.2 million in Q1 2025.